LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1

Cell Proliferation
Ming ZhangJinsong Wang

Abstract

Long non-coding RNAs (lncRNAs) have been demonstrated as crucial regulators in cancer, but whether they are involved in the immune response of cancer cells remains largely undiscovered. GATA3-AS1 is a novel lncRNA that was upregulated in breast cancer (BC) according to online databases. However, its role in triple-negative breast cancer (TNBC) was elusive. GATA3-AS1 expression in BC tissues and adjacent normal tissues was obtained from online databases. Loss-of-function assays were designed and conducted to verify the functional role of GATA3-AS1 in TNBC cells. Bioinformatic analysis and mechanism experiments were applied to explore the downstream molecular mechanism of GATA3-AS1. Similarly, the upstream mechanism which led to the upregulation of GATA3-AS1 in TNBC cells was also investigated. GATA3-AS1 was markedly overexpressed in TNBC tissues and cells. Knockdown of GATA3-AS1 suppressed TNBC cell growth and enhanced the resistance of TNBC cells to immune response. GATA3-AS1 induced the deubiquitination of PD-L1 through miR-676-3p/COPS5 axis. GATA3-AS1 destabilized GATA3 protein by promoting GATA3 ubiquitination. GATA3-AS1 contributed to TNBC progression and immune evasion through stabilizing PD-L1 protein and degrading GATA3 ...Continue Reading

References

Jul 3, 2009·Genes & Development·Jeremy E WiluszDavid L Spector
May 10, 2011·Trends in Cell Biology·Orly Wapinski, Howard Y Chang
Oct 1, 2011·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Junzo HamanishiIkuo Konishi
Jul 23, 2013·The Journal of Allergy and Clinical Immunology·Huan ZhangHui Wang
May 30, 2014·The Lancet Oncology·Lei FanPaul E Goss
Jun 15, 2015·Biochimica Et Biophysica Acta·Mollie E BarnardRulla M Tamimi
Nov 6, 2015·Nature Medicine·Maite Huarte
Aug 10, 2016·Biochemical and Biophysical Research Communications·Jing FangCheng Gong
Nov 22, 2016·Cancer Cell·Seung-Oe LimMien-Chie Hung
Jul 14, 2017·Cancer Research·Arunoday BhanSubhrangsu S Mandal
Oct 13, 2017·Journal of Translational Medicine·Paolo A AsciertoSandro Pignata
Nov 14, 2018·Frontiers in Immunology·Hunter R GibbonsThomas M Aune
Feb 1, 2019·International Journal of Biological Macromolecules·Wei ZhaoJuan Li
Sep 26, 2019·Journal of Histotechnology·Nahla Abdelfattah KamelShery Abdullah Ibrahim

❮ Previous
Next ❯

Citations

Jan 23, 2021·Signal Transduction and Targeted Therapy·Jiaxin LiuYong Song
Jun 7, 2021·Seminars in Cell & Developmental Biology·Ammad Ahmad FarooqiRossana Berardi
Jun 20, 2021·International Immunopharmacology·Melina FarshbafnadiNima Rezaei
Sep 10, 2021·Molecular Cancer·Wenxiao JiangXueqiong Zhu

❮ Previous
Next ❯

Methods Mentioned

BETA
deubiquitination
surgical resection
PCR
immunoprecipitation
Assay
flow cytometry
ubiquitination
RIP
histone acetylation
ChIP

Software Mentioned

PRISM
GraphPad

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.